SCHEMBL4510432

SCHEMBL4510432

CCNC(=O)OCC1CN(C2CCCCC2)C(=O)C1Cc1c(Cl)cccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 4/20 0.35
P2RX7 Q99572 3/20 0.35
GAA P10253 1/20 0.35
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
TSHR P16473 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14365304 0.85 PARP1 (0.37) TDP1KDM4EALDH1A1KMT2AGAA
SCHEMBL4501069 0.79 KMT2A (0.39) ALDH1A1KMT2ALMNAHTTSMN1; SMN2
SCHEMBL4500422 0.78 HSD11B1 (0.40) ALDH1A1KMT2ALMNASMN1; SMN2MEN1
SCHEMBL4518285 0.77 KMT2A (0.40) TDP1KDM4EALDH1A1KMT2AGAA
SCHEMBL4518281 0.76 SMN1; SMN2 (0.39) ALDH1A1KMT2ALMNAHTTSMN1; SMN2
SCHEMBL4503330 0.75 LMNA (0.39) TDP1ALDH1A1KMT2AGAALMNA
SCHEMBL13674435 0.74 KMT2A (0.45) KMT2AMEN1POLBL3MBTL1
SCHEMBL4516476 0.74 KMT2A (0.40) ALDH1A1KMT2AGAALMNAHTT
SCHEMBL4520571 0.74 LMNA (0.36) ALDH1A1KMT2ALMNAHTTSMN1; SMN2
SCHEMBL4515989 0.73 MEN1 (0.38) ALDH1A1KMT2ALMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 TDP1 1899/4885KDM4E 2703/4885ALDH1A1 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.